Oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB) reflect pro-inflammatory properties of Lp(a) (lipoprotein(a)). The effect of OxPL-apoB on major adverse cardiovascular events (MACE) in ...

Kritika Gaba, M.S., is a Scientific and Regulatory Affairs Compliance and Innovation Technician at The Coca-Cola Company in Toronto, Canada. Zifan Wan, Ph.D., is an Assistant Professor in the School ...

Phospholipases PLA1, PLA2, PLC, and PLD hydrolyze phospholipids to produce corresponding lysophospholipids and fatty acids. Red arrows indicate the corresponding hydrolysis sites. B) Phospholipases ...

Greg Daugherty has worked 25+ years as an editor and writer for major publications and websites. He is also the author of two books. Katie Miller is a consumer financial services expert. She worked ...

Research, headed by teams at Trinity College Dublin and University College Dublin, has uncovered how lipid-rich fluid in the abdomen, known as ascites, plays a central role in weakening the body’s ...

An ribonucleic acid (RNA) inhibitor, olpasiran (Amgen), which has shown it can lower lipoprotein(a) [Lp(a)] levels in patients with cardiovascular disease (CVD), has demonstrated in a phase 2 trial ...

Researchers develop innovative phospholipids that improve the functional delivery of mRNA via lipid nanoparticles, paving the way for advanced therapeutic applications. A groundbreaking study ...

Analysis could lead to future therapies to prevent deadly cardiac events. The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of ...

Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States Department of Molecular Biology and Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital ...

School of Biomedical Engineering, University of British Columbia, Vancouver V6T 1Z3, Canada Michael Smith Laboratories, University of British Columbia, Vancouver V6T 1Z4, Canada School of Biomedical ...